Cargando…

Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma

OBJECTIVE: Intratumoral hypoxia is an essential feature of hepatocellular carcinoma (HCC). Herein, we investigated the hypoxia-based heterogeneity and relevant clinical implication in HCC. METHODS: Three HCC cohorts: TCGA-LIHC, LICA-FR, and LIRI-JP were retrospectively gathered. Consensus clustering...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ke, Yang, Yanfang, Ma, Mingwei, Lu, Suping, Li, Junjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362578/
https://www.ncbi.nlm.nih.gov/pubmed/37481543
http://dx.doi.org/10.1186/s12957-023-03090-x
_version_ 1785076454415925248
author Li, Ke
Yang, Yanfang
Ma, Mingwei
Lu, Suping
Li, Junjie
author_facet Li, Ke
Yang, Yanfang
Ma, Mingwei
Lu, Suping
Li, Junjie
author_sort Li, Ke
collection PubMed
description OBJECTIVE: Intratumoral hypoxia is an essential feature of hepatocellular carcinoma (HCC). Herein, we investigated the hypoxia-based heterogeneity and relevant clinical implication in HCC. METHODS: Three HCC cohorts: TCGA-LIHC, LICA-FR, and LIRI-JP were retrospectively gathered. Consensus clustering analysis was utilized for hypoxia-based classification based upon transcriptome of hypoxia genes. Through LASSO algorithm, a hypoxia-relevant prognostic signature was built. Immunotherapeutic response was inferred through analyzing immune checkpoints, T cell inflamed score, TIDE score, and TMB score. RNF145 expression was measured in normoxic or hypoxic HCC cells. In RNF145-knockout cells, CCK-8, TUNEL, and scratch tests were implemented. RESULTS: HCC patients were classified into two hypoxia subtypes, with more advanced stages and poorer prognosis in cluster2 than cluster1. The heterogeneity in tumor infiltrating immune cells and genetic mutation was found between subtypes. The hypoxia-relevant prognostic model was proposed, composed of ANLN, CBX2, DLGAP5, FBLN2, FTCD, HMOX1, IGLV1-44, IL33, LCAT, LPCAT1, MKI67, PFN2, RNF145, S100A9, and SPP1). It was predicted that high-risk patients presented worse prognosis with an independent and reliable manner. Based upon high expression of immune checkpoints (CD209, CTLA4, HAVCR2, SIRPA, TNFRSF18, TNFRSF4, and TNFRSF9), high T cell inflamed score, low TIDE score and high TMB score, high-risk patients might respond to immunotherapy. Experimental validation showed that RNF145 was upregulated in hypoxic HCC cells, RNF145 knockdown attenuated proliferation and migration, but aggravated apoptosis in HCC cells. CONCLUSION: Altogether, the hypoxia-based classification and prognostic signature might be useful for prognostication and guiding treatment of HCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03090-x.
format Online
Article
Text
id pubmed-10362578
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103625782023-07-23 Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma Li, Ke Yang, Yanfang Ma, Mingwei Lu, Suping Li, Junjie World J Surg Oncol Research OBJECTIVE: Intratumoral hypoxia is an essential feature of hepatocellular carcinoma (HCC). Herein, we investigated the hypoxia-based heterogeneity and relevant clinical implication in HCC. METHODS: Three HCC cohorts: TCGA-LIHC, LICA-FR, and LIRI-JP were retrospectively gathered. Consensus clustering analysis was utilized for hypoxia-based classification based upon transcriptome of hypoxia genes. Through LASSO algorithm, a hypoxia-relevant prognostic signature was built. Immunotherapeutic response was inferred through analyzing immune checkpoints, T cell inflamed score, TIDE score, and TMB score. RNF145 expression was measured in normoxic or hypoxic HCC cells. In RNF145-knockout cells, CCK-8, TUNEL, and scratch tests were implemented. RESULTS: HCC patients were classified into two hypoxia subtypes, with more advanced stages and poorer prognosis in cluster2 than cluster1. The heterogeneity in tumor infiltrating immune cells and genetic mutation was found between subtypes. The hypoxia-relevant prognostic model was proposed, composed of ANLN, CBX2, DLGAP5, FBLN2, FTCD, HMOX1, IGLV1-44, IL33, LCAT, LPCAT1, MKI67, PFN2, RNF145, S100A9, and SPP1). It was predicted that high-risk patients presented worse prognosis with an independent and reliable manner. Based upon high expression of immune checkpoints (CD209, CTLA4, HAVCR2, SIRPA, TNFRSF18, TNFRSF4, and TNFRSF9), high T cell inflamed score, low TIDE score and high TMB score, high-risk patients might respond to immunotherapy. Experimental validation showed that RNF145 was upregulated in hypoxic HCC cells, RNF145 knockdown attenuated proliferation and migration, but aggravated apoptosis in HCC cells. CONCLUSION: Altogether, the hypoxia-based classification and prognostic signature might be useful for prognostication and guiding treatment of HCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03090-x. BioMed Central 2023-07-22 /pmc/articles/PMC10362578/ /pubmed/37481543 http://dx.doi.org/10.1186/s12957-023-03090-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Ke
Yang, Yanfang
Ma, Mingwei
Lu, Suping
Li, Junjie
Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
title Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
title_full Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
title_fullStr Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
title_full_unstemmed Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
title_short Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
title_sort hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362578/
https://www.ncbi.nlm.nih.gov/pubmed/37481543
http://dx.doi.org/10.1186/s12957-023-03090-x
work_keys_str_mv AT like hypoxiabasedclassificationandprognosticsignatureforclinicalmanagementofhepatocellularcarcinoma
AT yangyanfang hypoxiabasedclassificationandprognosticsignatureforclinicalmanagementofhepatocellularcarcinoma
AT mamingwei hypoxiabasedclassificationandprognosticsignatureforclinicalmanagementofhepatocellularcarcinoma
AT lusuping hypoxiabasedclassificationandprognosticsignatureforclinicalmanagementofhepatocellularcarcinoma
AT lijunjie hypoxiabasedclassificationandprognosticsignatureforclinicalmanagementofhepatocellularcarcinoma